Healthcare
Live Price
Offline$14.49
+0.00% today
Window Change
+153.77%
Window
Jun 23, 2025 → Apr 27, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 213 bars · Jun 23, 2025 → Apr 27, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Amicus Therapeutics, Inc. (FOLD) is a Healthcare stock with a market cap of $4.55B and listed on NASDAQ. The stock last traded around $14.49 and up 153.8% across the available one-year price window (Jun 23, 2025 → Apr 27, 2026). Baseline metrics include revenue growth of +20.0%, EPS growth of +51.2%, a dividend yield of 0.0%. What stands out right now is revenue +20.0%, EPS +51.2%, free cash flow +179.7% with operating margin 5.2% and ROIC -645.7%. Valuation sits in the middle of the pack at price/sales 7.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FOLD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
FOLD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
FOLD Max Drawdown
-10.04%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for FOLD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$305.5M
-7.2% YoY
FY Net Income
-$250.5M
-5.9% YoY
Free Cash Flow
-$206.4M
-21.2% YoY
Revenue Growth
+20.0%
EPS Growth
+51.2%
Gross Margin
87.9%
Net Margin
-4.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 634M | 528M | 399M | 329M | 306M |
| Gross Profit | 554M | 475M | 362M | 291M | 271M |
| Operating Income | 34M | 25M | -77M | -212M | -206M |
| EBITDA | 54M | 29M | -92M | -200M | -203M |
| Net Income | -27M | -56M | -152M | -237M | -250M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 214M | 214M | 247M | 149M | 245M |
| Total Assets | 950M | 785M | 778M | 724M | 905M |
| Total Liabilities | 676M | 591M | 618M | 601M | 598M |
| Shareholder Equity | 274M | 194M | 160M | 123M | 307M |
| Total Debt | 483M | 444M | 445M | 452M | 440M |
| Net Debt | 269M | 230M | 198M | 303M | 195M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
202M
-21.6% YoY
Capital Expenditures
4M
-3.1% YoY
Free Cash Flow
206M
-21.2% YoY
Key ratios
Gross Margin
87.9%
Operating Margin
5.2%
Net Margin
-4.3%
ROE
-12.0%
Debt / Equity
1.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.